Dashboard
Manage Tickers

CANFCan-Fite BioPharma Ltd.

NYSE canfite.com


$ 3.70 $ -0.02 (-0.55 %)    

Wednesday, 17-Jul-2024 12:57:35 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 482.23 $ -14.57 (-2.94 %)
DIA $ 412.29 $ 2.27 (0.55 %)
SPY $ 557.05 $ -7.92 (-1.4 %)
TLT $ 94.21 $ 0.02 (0.02 %)
GLD $ 227.29 $ -1.06 (-0.46 %)
$ 3.64
$ 3.70
$ 0.00 x 0
$ 3.75 x 100
$ 3.70 - $ 3.70
$ 1.81 - $ 4.48
113,658
na
4.95B
$ 0.72
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

ef-hutton-initiates-coverage-on-can-fite-biofarma-with-buy-rating-announces-price-target-of-10
EF Hutton Initiates Coverage On Can Fite B...
07/17/2024 12:28:21

EF Hutton analyst Jason Kolbert initiates coverage on Can Fite Biofarma (AMEX:CANF) with a Buy rating and announces Price Ta...

can-fite-submits-application-to-fda-for-orphan-drug-designation-for-its-drug-candidate-namodenoson-in-the-treatment-of-pancreatic-carcinoma
Can-Fite Submits Application To FDA For Or...
07/11/2024 11:04:30

Can-Fite plans to start shortly a Phase IIa clinical study that will be a multicenter open-label trial in patients with advance...

can-fite-biopharma-announced-that-a-patient-with-liver-decompensated-cirrhosis-who-was-treated-with-namodenoson-at-the-soroka-medical-center-in-israel-under-compassionate-use-showed-an-improvement-in-liver-indices
Can-Fite Biopharma Announced That A Patien...
07/01/2024 11:10:17

This Drug Candidate Is Currently Used In A Pivotal Phase 3 Study For Patients With Advanced Liver Cancer And A Phase 2b Study F...

can-fite-biopharma-says-its-veterinary-partner-vetbiolix-reported-positive-results-in-an-osteoarthritis-multicenter-clinical-study-in-dogs-treated-with-piclidenoson
Can-fite Biopharma Says Its Veterinary Par...
06/28/2024 11:07:27

can-fite-announces-new-findings-on-namodenosons-dual-anti-cancer-and-liver-protective-effects
Can-Fite Announces New Findings on Namoden...
06/24/2024 11:04:22

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule dr...

12-health-care-stocks-moving-in-fridays-after-market-session
12 Health Care Stocks Moving In Friday's A...
06/14/2024 20:31:12

why-ammo-shares-are-trading-lower-by-over-19-here-are-other-stocks-moving-in-fridays-mid-day-session
Why AMMO Shares Are Trading Lower By Over ...
06/14/2024 18:13:08

can-fite-biopharma-says-its-phase-3-study-for-namodenoson-for-advanced-liver-cancer-is-31-recruiting-medical-centers-namodenoson-has-orphan-drug-status-from-fda-and-european-medicines-agency-and-fda-fast-track-status
Can-Fite Biopharma Says Its Phase 3 Study ...
06/05/2024 11:18:20

A compassionate use program has also been ongoing in Israel and Romania. 

hc-wainwright--co-reiterates-buy-on-can-fite-biofarma-maintains-18-price-target
HC Wainwright & Co. Reiterates Buy on Can ...
05/09/2024 17:47:26

HC Wainwright & Co. analyst Vernon Bernardino reiterates Can Fite Biofarma (AMEX:CANF) with a Buy and maintains $18 pric...

the-fda-has-granted-investigational-new-drug-clearance-for-can-fite-biopharmas-namodenoson-for-metabolic-dysfunction-associated-steatohepatitis-also-known-as-non-alcoholic-steatohepatitis-for-the-companys-ongoing-phase-2b-study
The FDA Has Granted Investigational New Dr...
05/09/2024 12:21:58

can-fite-received-notice-of-allowance-from-the-european-patent-office-for-the-treatment-of-erectile-dysfunction-with-cf602
Can-Fite Received Notice of Allowance from...
05/06/2024 11:04:23

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule dru...

12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's...
04/25/2024 12:06:47

can-fite-biopharma-announced-it-published-an-article-in-the-experimental-and-therapeutic-medicine-journal-long-term-complete-response-to-namodenoson-in-liver-cancer-with-child-pugh-b-cirrhosis
Can-Fite Biopharma Announced It Published ...
04/25/2024 11:28:46

The Patient Participated In The Phase Ii Liver Cancer Study And Has Been Treated With Namodenoson For >7 Years Under Compass...

can-fites-namodenoson-featured-in-biomedicines-for-liver-cancer-and-mash-treatment-insights
Can-Fite's Namodenoson Featured in Biomedi...
04/15/2024 11:06:38

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule dr...

can-fite-biopharma-submits-fda-with-an-ind-application-to-conduct-phase-iib-clinical-trial-of-namodenoson-in-mash-patients
Can-Fite BioPharma Submits FDA with an IND...
04/03/2024 11:03:06

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule dru...

can-fite-biofarma-q4-earnings-insights
Can Fite Biofarma: Q4 Earnings Insights
03/28/2024 11:50:05

can-fite-biofarma-fy-gaap-eps-001-same-yoy-sales-74300k-down-from-81000k-yoy
Can Fite Biofarma FY GAAP EPS $(0.01), Sam...
03/28/2024 11:23:54

Can Fite Biofarma (AMEX:CANF) reported quarterly losses of $(0.01) per share. This is unchanged from the same period last year....

can-fite-biopharma-announced-notice-of-allowance-in-canada-for-its-patent-application-regarding-se-of-namodenoson-for-the-reduction-of-liver-fat-in-patients-with-nash
Can-Fite BioPharma Announced Notice Of All...
02/28/2024 12:12:11

can-fite-expands-the-out-licensing-deal-with-ewopharma-to-include-the-pancreatic-cancer-indication
Can-Fite Expands the Out-Licensing Deal wi...
01/30/2024 12:03:19

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule dru...

can-fites-latest-innovation-namodenoson-shows-significant-results-in-obesity-reduction
Can-Fite's Latest Innovation: Namodenoson ...
12/20/2023 12:07:16

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule dr...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)
07/23/2024 Fastly, Inc. (FSLY)
07/29/2024 Enphase Energy, Inc. (ENPH)
07/30/2024 Rivian Automotive, Inc. (RIVN)
07/30/2024 Hertz Global Holdings, Inc. (HTZ)
08/02/2024 Humana Inc. (HUM)
08/05/2024 Marinus Pharmaceuticals, Inc. (MRNS)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)